Your browser doesn't support javascript.
loading
Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system.
Sabathé, Camille; Casey, Romain; Vukusic, Sandra; Leray, Emmanuelle; Mathey, Guillaume; De Sèze, Jérôme; Ciron, Jonathan; Wiertlewski, Sandrine; Ruet, Aurélie; Pelletier, Jean; Zéphir, Hélène; Michel, Laure; Lebrun-Frenay, Christine; Moisset, Xavier; Thouvenot, Eric; Camdessanché, Jean-Philippe; Bakchine, Serge; Stankoff, Bruno; Al Khedr, Abdullatif; Cabre, Philippe; Maillart, Elisabeth; Berger, Eric; Heinzlef, Olivier; Hankiewicz, Karolina; Moreau, Thibault; Gout, Olivier; Bourre, Bertrand; Wahab, Abir; Labauge, Pierre; Montcuquet, Alexis; Defer, Gilles; Maurousset, Aude; Maubeuge, Nicolas; Dimitri Boulos, Dalia; Ben Nasr, Haïfa; Nifle, Chantal; Casez, Olivier; Laplaud, David-Axel; Foucher, Yohann.
Afiliación
  • Sabathé C; Université de Nantes, Université de Tours, Inserm, UMR1246 Sphere, Nantes, France.
  • Casey R; Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France/Hospices Civils de Lyon, Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Lyon, France/Observatoire Français de la Sclérose en Plaques, Centre de Recherche en Neurosciences de Lyon, Lyon, F
  • Vukusic S; Hospices Civils de Lyon, Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuro-inflammation, Lyon, France/Observatoire Français de la Sclérose en Plaques, Centre de Recherche en Neurosciences de Lyon, Lyon, France/Faculté de médecine Lyon Est, Université Claude Bernard Lyon
  • Leray E; EHESP, Université de Rennes, Rennes, France.
  • Mathey G; Department of Neurology, Nancy University Hospital, Hôpital Central, Service de Neurologie, Nancy, France/Université de Lorraine, Nancy, France.
  • De Sèze J; Department of Neurology and Clinical Investigation Center, CHU de Strasbourg, Strasbourg, France.
  • Ciron J; Department of Neurology, Hôpital Pierre-Paul Riquet, CHU de Toulouse, Toulouse, France.
  • Wiertlewski S; Université de Nantes, Nantes, France/Service de Neurologie, Centre de Ressources et de Compétences Sclérose en Plaques, Centre Hospitalier Universitaire de Nantes, Nantes, France.
  • Ruet A; University of Bordeaux, Bordeaux, France/Department of Neurology, CHU de Bordeaux, Bordeaux, France.
  • Pelletier J; Aix Marseille University, APHM, Hôpital de la Timone, Pôle de Neurosciences Cliniques, Service de Neurologie, Marseille, France.
  • Zéphir H; University of Lille, Lille, France.
  • Michel L; Clinical Neuroscience Centre, Rennes University Hospital, Rennes, France/Microenvironment, Cell Differentiation, Immunology and Cancer Unit, Rennes, France/Neurology Department, Rennes University Hospital, Rennes, France.
  • Lebrun-Frenay C; Service de neurologie, CRCSEP, CHU de Nice, UR2CA-URRIS, Nice, France.
  • Moisset X; Université Clermont Auvergne, CHU de Clermont-Ferrand, Inserm, Neuro-Dol, Clermont-Ferrand, France.
  • Thouvenot E; Department of Neurology, Nimes University Hospital, Nimes, France/Institut de Génomique Fonctionnelle, Université de Montpellier, Montpellier, France.
  • Camdessanché JP; Department of Neurology, Hôpital Nord, CHU de Saint-Étienne, Saint-Étienne, France.
  • Bakchine S; CHU de Reims, Reims, France.
  • Stankoff B; Sorbonne Universités, Brain and Spine Institute, ICM, Hôpital de la Pitié Salpêtrière, Paris, France/Department of Neurology, AP-HP, Saint-Antoine Hospital, Paris, France.
  • Al Khedr A; Department of Neurology, CHU d'Amiens, Amiens, France.
  • Cabre P; Department of Neurology, CHU de la Martinique, Fort-de-France, France.
  • Maillart E; Département de Neurologie, AP-HP, Hôpital Pitié-Salpêtrière, Paris, France/Centre de Ressources et de Compétences SEP, Paris, France.
  • Berger E; Service de Neurologie Besançon, CHU de Besançon, Besançon, France.
  • Heinzlef O; Department of Neurology, Hôpital de Poissy, Poissy, France.
  • Hankiewicz K; Department of Neurology, Centre Hospitalier de Saint-Denis, Hôpital Pierre Delafontaine, Saint-Denis, France.
  • Moreau T; Department of Neurology, CHU de Dijon, Dijon, France.
  • Gout O; Department of Neurology, Fondation Rothschild, Paris, France.
  • Bourre B; Rouen University Hospital, Rouen, France.
  • Wahab A; Department of Neurology, AP-HP, Hôpital Henri Mondor, Créteil, France.
  • Labauge P; CRC SEP, Montpellier University Hospital, INSERM, Université de Montpellier, Montpellier, France.
  • Montcuquet A; Department of Neurology, Hôpital Dupuytren, CHU de Limoges, Limoges, France.
  • Defer G; CHU de Caen, MS Expert Centre, Department of Neurology, Normandy University, Caen, France.
  • Maurousset A; CRC SEP and Department of Neurology, Hôpital Bretonneau, CHU de Tours, Tours, France.
  • Maubeuge N; Department of Neurology, Hôpital Jean Bernard, CHU La Milétrie, Poitiers, France.
  • Dimitri Boulos D; Department of Neurology, CHU Bicêtre, Le Kremlin-Bicêtre, France.
  • Ben Nasr H; Department of Neurology, Hôpital Sud Francilien, Corbeil-Essonnes, France.
  • Nifle C; Department of Neurology, Hopital Andre Mignot, Le Chesnay, France.
  • Casez O; Department of Neurology, CHU Grenoble Alpes, Grenoble, France.
  • Laplaud DA; Université de Nantes, Nantes, France/Service de Neurologie, Centre de Ressources et de Compétences Sclérose en Plaques, Centre Hospitalier Universitaire de Nantes, Nantes, France.
  • Foucher Y; Yohann Foucher CIC 1402, CHU de Poitiers, Université de Poitiers, Poitiers, France.
Mult Scler ; 29(2): 236-247, 2023 02.
Article en En | MEDLINE | ID: mdl-36515394
ABSTRACT

BACKGROUND:

In relapsing-remitting multiple sclerosis (RRMS), early identification of suboptimal responders can prevent disability progression.

OBJECTIVE:

We aimed to develop and validate a dynamic score to guide the early decision to switch from first- to second-line therapy.

METHODS:

Using time-dependent propensity scores (PS) from a French cohort of 12,823 patients with RRMS, we constructed one training and two validation PS-matched cohorts to compare the switched patients to second-line treatment and the maintained patients. We used a frailty Cox model for predicting individual hazard ratios (iHRs).

RESULTS:

From the validation PS-matched cohort of 348 independent patients with iHR ⩽ 0.69, we reported the 5-year relapse-free survival at 0.14 (95% confidence interval (CI) 0.09-0.22) for the waiting group and 0.40 (95% CI 0.32-0.51) for the switched group. From the validation PS-matched cohort of 518 independent patients with iHR > 0.69, these values were 0.37 (95% CI 0.30-0.46) and 0.44 (95% CI 0.37-0.52), respectively.

CONCLUSIONS:

By using the proposed dynamic score, we estimated that at least one-third of patients could benefit from an earlier switch to prevent relapse.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Francia